

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/502.442
--------------------	------------

Filing Date	22 July 2004
-------------	--------------

First Named Inventor	BRAUN, et al.
----------------------	---------------

Art Unit	Unassigned
----------	------------

Examiner Name	Unassigned
---------------	------------

Attorney Docket Number	4121-171
------------------------	----------

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

/Maria Leavitt/

Date _____


Considered

03/22/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/502,442		
		Filing Date	22 July 2004		
		First Named Inventor	BRAUN, et al.		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	4121-171

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ML	AB	BERGER, ET AL., "Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide ..." Breast Cancer Research, 2001, Vol 3, pp. 28-35	
/ML/	AC	HECKL, ET AL., "CNN-Gd3+ Enables Cell Nucleus Molecular Imaging of Prostate Cancer Cells: The Last 600 nm", Cancer Research, 2002, Vol. 2, pp. 7018-7024	
/ML/	AD	R.B. MERRIFIELD, "The Synthesis of a Tetrapeptide", Journal of American Chemical Society, 1963, Vol 85, pp. 2149-2154	
/ML/	AE	CARPINO, ET AL., "The 9-Fluorenylmethoxycarbonyl Amino-Protecting Group", Journal of Organic Chemistry, 1972, Vol 37, pp. 3404-3409	
/ML/	AF	SLAMON, ET AL., "Use of Chemotherapy Plus a Monoclonal Antibody Against Her2 for Metastatic Breast...", The New England Journal of Medicine, 2001, Vol 344, pp. 783-788	
/ML/	AG	POOGA, ET AL., "Cell Penetration by Transportan", The FASEB Journal, 1998, Vol 12, pp. 67-77	
/ML/	AH	DEROSSI, ET AL., "Trojan peptides: the penetratin system for intracellular delivery", Trends in Cell Biology, 1998, Vol 8, pp. 84-87	

Examiner Signature	/Maria Leavitt/	Date Considered	03/22/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.